Prognostic Significance of Chromogranin A Expression in the Initial and Second Biopsies in Metastatic Prostate Cancer

Overview

Journal J Clin Med

Specialty General Medicine

Date 2023 May 27

PMID 37240468

Authors

Zhuo Huang

Ying Tang

Yuyan Wei

Jingyu Qian

Yifan Kang

Duohao Wang

Miao Xu

Ling Nie

Xueqin Chen

Ni Chen

Qiao Zhou

Affiliations

Soon will be listed here.

Abstract

Neuroendocrine differentiation (NED) characterized by the expression of neuroendocrine markers, such as chromogranin A (CgA), is frequently observed in advanced prostate cancer (PCa), the prognostic significance of which is still controversial. Here we specifically addressed the issue of the potential prognostic value of CgA expression in advanced-stage PCa patients with distant metastases and its change over time from metastatic hormone-sensitive (mHSPC) to metastatic castration-resistant prostate cancer (mCRPC). CgA expression was assessed immunohistochemically in initial biopsies of mHSPC, as well as in second biopsies of mCRPC in sixty-eight patients, and its correlation with prognosis (together with conventional clinicopathologic parameters) was analyzed using the Kaplan-Meier method and Cox proportional hazard model. We found that CgA expression was an independent adverse prognostic factor for both mHSPC (CgA positivity ≥ 1%, HR = 2.16, 95% CI: 1.04-4.26, = 0.031) and mCRPC (CgA ≥ 10%, HR = 20.19, 95% CI: 3.04-329.9, = 0.008). CgA positivity generally increased from mHSPC to mCRPC and was a negative prognosticator. The assessment of CgA expression may help with the clinical evaluation of advanced-stage patients with distant metastases.

Citing Articles

Molecular diagnostics of prostate cancer: impact of molecular tests.

Azzalini E, Bonin S Asian J Androl. 2024; 26(6):562-566.

PMID: 38738960 PMC: 11614165. DOI: 10.4103/aja202411.

References

Liu Y, Zhao S, Wang J, Zhu Z, Luo L, Li E . Serum Neuroendocrine Markers Predict Therapy Outcome of Patients with Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis. Urol Int. 2018; 102(4):373-384. DOI: 10.1159/000495512. View

Kokubo H, Yamada Y, Nishio Y, Fukatsu H, Honda N, Nakagawa A . Immunohistochemical study of chromogranin A in Stage D2 prostate cancer. Urology. 2005; 66(1):135-40. DOI: 10.1016/j.urology.2005.01.026. View

Epstein J, Amin M, Beltran H, Lotan T, Mosquera J, Reuter V . Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol. 2014; 38(6):756-67. PMC: 4112087. DOI: 10.1097/PAS.0000000000000208. View

Mitsui Y, Arichi N, Hiraki M, Harada Y, Yasumoto H, Shiina H . Tissue Chromogranin A Expression during Prostate Cancer Progression: Prediction of Chemosensitivity. Urol J. 2015; 12(3):2165-72. View

Dardenne E, Beltran H, Benelli M, Gayvert K, Berger A, Puca L . N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. Cancer Cell. 2016; 30(4):563-577. PMC: 5540451. DOI: 10.1016/j.ccell.2016.09.005. View

Seo E, Jee B, Chung J, Song W, Sung H, Jeon H . Repression of SLC22A3 by the AR-V7/YAP1/TAZ axis in enzalutamide-resistant castration-resistant prostate cancer. FEBS J. 2022; 290(6):1645-1662. DOI: 10.1111/febs.16657. View

Mankuzhy N, Almahariq M, Ye H, Amin M, Stone B, Krauss D . Investigation of the Prognostic Significance of Neuroendocrine Differentiation in Gleason Score 7 to 10 Prostate Adenocarcinoma in Patients With Distant Metastasis After Definitive Radiotherapy. Am J Clin Pathol. 2020; 155(6):879-886. DOI: 10.1093/ajcp/aqaa199. View

Bech P, Martin N, Ramachandran R, Bloom S . The biochemical utility of chromogranin A, chromogranin B and cocaine- and amphetamine-regulated transcript for neuroendocrine neoplasia. Ann Clin Biochem. 2013; 51(Pt 1):8-21. DOI: 10.1177/0004563213489670. View

Grimaldi F, Valotto C, Barbina G, Visentini D, Trianni A, Cerruto M . The possible role of chromogranin A as a prognostic factor in organ-confined prostate cancer. Int J Biol Markers. 2006; 21(4):229-34. DOI: 10.1177/172460080602100406. View

10.

Bluemn E, Coleman I, Lucas J, Coleman R, Hernandez-Lopez S, Tharakan R . Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. Cancer Cell. 2017; 32(4):474-489.e6. PMC: 5750052. DOI: 10.1016/j.ccell.2017.09.003. View

11.

Berruti A, Bollito E, Cracco C, Volante M, Ciccone G, Porpiglia F . The prognostic role of immunohistochemical chromogranin a expression in prostate cancer patients is significantly modified by androgen-deprivation therapy. Prostate. 2010; 70(7):718-26. DOI: 10.1002/pros.21104. View

12.

Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T . EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Eur Urol. 2016; 71(4):630-642. DOI: 10.1016/j.eururo.2016.08.002. View

13.

Ku S, Rosario S, Wang Y, Mu P, Seshadri M, Goodrich Z . Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science. 2017; 355(6320):78-83. PMC: 5367887. DOI: 10.1126/science.aah4199. View

14.

Aggarwal R, Huang J, Alumkal J, Zhang L, Feng F, Thomas G . Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. J Clin Oncol. 2018; 36(24):2492-2503. PMC: 6366813. DOI: 10.1200/JCO.2017.77.6880. View

15.

Shan J, Al-Muftah M, Al-Kowari M, Abuaqel S, Al-Rumaihi K, Al-Bozom I . Targeting Wnt/EZH2/microRNA-708 signaling pathway inhibits neuroendocrine differentiation in prostate cancer. Cell Death Discov. 2019; 5:139. PMC: 6768854. DOI: 10.1038/s41420-019-0218-y. View

16.

Conteduca V, Oromendia C, Eng K, Bareja R, Sigouros M, Molina A . Clinical features of neuroendocrine prostate cancer. Eur J Cancer. 2019; 121:7-18. PMC: 6803064. DOI: 10.1016/j.ejca.2019.08.011. View

17.

Watson P, Arora V, Sawyers C . Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 2015; 15(12):701-11. PMC: 4771416. DOI: 10.1038/nrc4016. View

18.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

19.

Kim E, Kim M, Woo D, Shin Y, Shin J, Chang N . Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell. 2013; 23(6):839-52. PMC: 4109796. DOI: 10.1016/j.ccr.2013.04.008. View

20.

Niedworok C, Tschirdewahn S, Reis H, Lehmann N, Szucs M, Nyirady P . Serum Chromogranin A as a Complementary Marker for the Prediction of Prostate Cancer-Specific Survival. Pathol Oncol Res. 2016; 23(3):643-650. DOI: 10.1007/s12253-016-0171-5. View